{"slug":"melanoma","tag":"melanoma","variants":["melanoma"],"description":"People whose work centres on melanoma.","count":24,"kinds":{"person":24},"related":[{"slug":"immunotherapy","tag":"immunotherapy","shared":9},{"slug":"trialist","tag":"trialist","shared":8},{"slug":"adjuvant","tag":"adjuvant","shared":3},{"slug":"clinician-scientist","tag":"clinician-scientist","shared":3},{"slug":"leadership","tag":"leadership","shared":3},{"slug":"neoadjuvant","tag":"neoadjuvant","shared":3},{"slug":"surgery","tag":"surgery","shared":3},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":2},{"slug":"australia","tag":"australia","shared":1},{"slug":"brain-metastases","tag":"brain-metastases","shared":1},{"slug":"cell-therapy","tag":"cell-therapy","shared":1},{"slug":"colorectal-cancer","tag":"colorectal cancer","shared":1}],"records":[{"id":"dirk-schadendorf","kind":"person","name":"Dirk Schadendorf","route":"/people/dirk-schadendorf/","tldr":"Melanoma expert who directs the West German Cancer Center at University Hospital Essen."},{"id":"susana-puig","kind":"person","name":"Susana Puig","route":"/people/susana-puig/","tldr":"Dermatologist and melanoma researcher who directs IDIBAPS, the research institute of Hospital Clínic de Barcelona."},{"id":"janja-ocvirk","kind":"person","name":"Janja Ocvirk","route":"/people/janja-ocvirk/","tldr":"Medical oncologist and Medical Director of the Institute of Oncology Ljubljana, with research in melanoma and colorectal cancer."},{"id":"georgina-long","kind":"person","name":"Georgina V. Long","route":"/people/georgina-long/","tldr":"Melanoma trialist who led COMBI-d, COMBI-AD and NADINA, moving immunotherapy before surgery for stage III disease."},{"id":"jedd-wolchok","kind":"person","name":"Jedd D. Wolchok","route":"/people/jedd-wolchok/","tldr":"Led CheckMate 067, the trial whose ten-year data showed half of advanced melanoma patients on nivolumab plus ipilimumab are alive."},{"id":"caroline-robert","kind":"person","name":"Caroline Robert","route":"/people/caroline-robert/","tldr":"Led KEYNOTE-006 and COMBI-v, the trials that made pembrolizumab and dabrafenib-trametinib standards in melanoma."},{"id":"hussein-tawbi","kind":"person","name":"Hussein A. Tawbi","route":"/people/hussein-tawbi/","tldr":"Led RELATIVITY-047, which made relatlimab the first approved LAG-3 inhibitor, and the trial that showed immunotherapy works in melanoma brain metastases."},{"id":"paolo-ascierto","kind":"person","name":"Paolo A. Ascierto","route":"/people/paolo-ascierto/","tldr":"Italian melanoma oncologist who co-led CheckMate 238, CheckMate 067 and the COLUMBUS BRAF/MEK trial."},{"id":"michael-postow","kind":"person","name":"Michael A. Postow","route":"/people/michael-postow/","tldr":"Led CheckMate 069, the first randomised trial of nivolumab plus ipilimumab, and defines how to manage immunotherapy side effects."},{"id":"jeffrey-weber","kind":"person","name":"Jeffrey S. Weber","route":"/people/jeffrey-weber/","tldr":"Led CheckMate 238, which made adjuvant nivolumab standard after melanoma surgery, and co-led the mRNA vaccine trial KEYNOTE-942."},{"id":"sapna-patel","kind":"person","name":"Sapna P. Patel","route":"/people/sapna-patel/","tldr":"Led SWOG S1801, the trial that showed giving pembrolizumab before surgery, not just after, improves outcomes in melanoma."},{"id":"jason-luke","kind":"person","name":"Jason J. Luke","route":"/people/jason-luke/","tldr":"Led KEYNOTE-716, which extended adjuvant pembrolizumab to high-risk stage II melanoma."},{"id":"mark-faries","kind":"person","name":"Mark B. Faries","route":"/people/mark-faries/","tldr":"Surgeon who led MSLT-II, showing that removing all lymph nodes after a positive sentinel node does not improve melanoma survival."},{"id":"reinhard-dummer","kind":"person","name":"Reinhard Dummer","route":"/people/reinhard-dummer/","tldr":"Swiss dermato-oncologist who led COLUMBUS and the neoadjuvant talimogene laherparepvec studies."},{"id":"jennifer-wargo","kind":"person","name":"Jennifer A. Wargo","route":"/people/jennifer-wargo/","tldr":"Surgeon-scientist who showed the gut microbiome shapes response to immunotherapy and led early neoadjuvant melanoma trials."},{"id":"inge-marie-svane","kind":"person","name":"Inge Marie Svane","route":"/people/inge-marie-svane/","tldr":"Led the Dutch-Danish trial that proved TIL therapy beats ipilimumab in melanoma, the first randomised win for a cell therapy in a solid tumour."},{"id":"howard-kaufman","kind":"person","name":"Howard L. Kaufman","route":"/people/howard-kaufman/","tldr":"Led OPTiM, the trial that made talimogene laherparepvec the first approved oncolytic virus therapy."},{"id":"paul-chapman","kind":"person","name":"Paul B. Chapman","route":"/people/paul-chapman/","tldr":"New York melanoma doctor who was lead author of BRIM-3, the trial that showed vemurafenib lengthens survival in BRAF-mutant melanoma and launched targeted therapy for the disease."},{"id":"michael-atkins","kind":"person","name":"Michael B. Atkins","route":"/people/michael-atkins/","tldr":"Washington oncologist who led DREAMseq, the trial that showed people with BRAF-mutant melanoma live longer if immunotherapy is given before targeted therapy rather than after."},{"id":"john-kirkwood","kind":"person","name":"John M. Kirkwood","route":"/people/john-kirkwood/","tldr":"Pittsburgh melanoma doctor who ran the interferon trials that were the first adjuvant treatment for high-risk melanoma, and later led CheckMate 76K on adjuvant nivolumab for stage II disease."},{"id":"jeffrey-gershenwald","kind":"person","name":"Jeffrey E. Gershenwald","route":"/people/jeffrey-gershenwald/","tldr":"Houston surgeon who chaired the melanoma expert panel for the eighth edition of the AJCC staging system, the classification doctors use to describe how far a melanoma has spread."},{"id":"piotr-rutkowski","kind":"person","name":"Piotr Rutkowski","route":"/people/piotr-rutkowski/","tldr":"Polish surgical oncologist who led the pooled EORTC and SWOG trials showing that imatinib shrinks dermatofibrosarcoma protuberans, a rare skin sarcoma driven by a PDGFB fusion."},{"id":"jean-jacques-grob","kind":"person","name":"Jean-Jacques Grob","route":"/people/jean-jacques-grob/","tldr":"Marseille dermatologist who led KEYNOTE-629, which established pembrolizumab for advanced cutaneous squamous-cell carcinoma, and who has been a senior investigator on many European melanoma trials."},{"id":"ralf-gutzmer","kind":"person","name":"Ralf Gutzmer","route":"/people/ralf-gutzmer/","tldr":"German dermato-oncologist who was lead author of IMspire150, the trial that added atezolizumab to vemurafenib and cobimetinib in BRAF-mutant melanoma."}]}